Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

286
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
286
Psychosurgery01:30

Psychosurgery

106
Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
106
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

246
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
246
Drug Therapy01:28

Drug Therapy

100
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
100
Altered States of Awareness01:06

Altered States of Awareness

470
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
470
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Balancing safety and access in Oregon's psilocybin services.

The International journal on drug policy·2026
Same author

Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.

Healthcare (Basel, Switzerland)·2026
Same author

Still invisible? Legal and ethical treatment of intersex individuals in China.

Journal of law and the biosciences·2026
Same author

Regulating genetic discrimination in Chinese employment: insights from thalassemia-related cases.

Journal of law and the biosciences·2026
Same author

Imagining Genomics and Population Health in 2050: Anticipating Future Research, Policy, and Governance Needs.

Public health genomics·2026
Same author

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.

Palliative medicine·2026
Same journal

Prohibited AI Practices in Healthcare under the European Artificial Intelligence Act.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same journal

Probing the Prevalence of Pharmaceutical Corruption.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same journal

Regulatory Guidance for the Return of Raw Genomic Data to Research Participants: A Qualitative Interview Study.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same journal

Supported Decision-Making and the Inclusion of People who Lack Decisional Capacity in Greater than Minimal Risk Research.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same journal

Using Supported Decision-Making to Promote Value-Aligned Research Participation.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same journal

Intellectual Disability and Supported Decision-Making in Clinical Research: Anticipating Ethical Challenges.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
See all related articles

Related Experiment Video

Updated: Sep 13, 2025

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.4K

Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians' Concerns.

Katherine Cheung1, Maxwell Brodie2, Sue-Ling Chang3

  • 1National Institutes of Health, Bethesda, United States.

The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|July 31, 2025
PubMed
Summary
This summary is machine-generated.

Physicians face potential medical malpractice risks when prescribing psilocybin treatment due to evolving standards. Developing clear medical guidelines and training is crucial for safe psilocybin therapy integration.

Keywords:
liabilitymalpracticenegligencepsilocybinpsilocybin-assisted therapypsychedelic treatment

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K
Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
09:03

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management

Published on: March 28, 2025

618

Related Experiment Videos

Last Updated: Sep 13, 2025

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.4K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K
Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
09:03

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management

Published on: March 28, 2025

618

Area of Science:

  • Medical Ethics
  • Pharmacology
  • Psychiatry

Background:

  • Psilocybin treatment shows promise for conditions like end-of-life anxiety and depression.
  • Physician hesitancy to prescribe psilocybin stems from stigma and malpractice concerns.

Purpose of the Study:

  • To investigate the risk of medical malpractice liability for physicians administering psilocybin treatment.
  • To analyze the current regulatory landscape for psilocybin in Canada.

Main Methods:

  • Exploratory vignettes used to illustrate malpractice claim relevance and limitations.
  • Analysis of the Canadian regulatory framework for psilocybin therapy.

Main Results:

  • Lack of standardized medical protocols, training, and credentialing increases liability risks.
  • Vignettes highlight the complexities and boundaries of malpractice in psilocybin treatment.

Conclusions:

  • Establishing clear medical standards and training is essential to mitigate malpractice risks.
  • Further clinical trials and knowledge sharing are needed to develop best practices for psilocybin therapy.